{"dosingInfo":[{"id":1447949827,"literature":[{"id":14775937,"resourceId":"21692613","title":"A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.","authors":["Newman William G","Payne Katherine","Tricker Karen","Roberts Stephen A","Fargher Emily","Pushpakom Sudeep","Alder Jane E","Sidgwick Gary P","Payne Debbie","Elliott Rachel A","Heise Marco","Elles Robert","Ramsden Simon C","Andrews Julie","Houston J Brian","Qasim Faeiza","Shaffer Jon","Griffiths Christopher E M","Ray David W","Bruce Ian","Ollier William E R","TARGET study recruitment team"],"journal":"Pharmacogenomics","month":6,"sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21692613","type":"article","year":2011}],"markdown":{"id":1447980614,"html":"<h2 id=\"main-findings\">Main Findings</h2>\n<p><strong>There was no significant difference in likelihood of discontinuing azathioprine due to an adverse reaction in the first 4 months of therapy when comparing patients who were dosed based on <em>TPMT</em> genotype and those who received a standard dose (p=0.74)</strong></p>\n<h2 id=\"dosing-protocol\">Dosing Protocol</h2>\n<table class=\"table\">\n<thead>\n<tr><th>Pharmacogenetic arm (n=167)</th><th></th><th></th></tr>\n</thead>\n<tbody>\n<tr><td><strong>Genotype</strong></td><td><strong>Number</strong></td><td><strong>Dosing Advice</strong></td></tr>\n<tr><td>TPMT wild-type</td><td>n=148</td><td>Maintenance dose of 1.5 - 3 mg/kg/day</td></tr>\n<tr><td>TPMT *1/*2, *1/*3A, or *1/*3C</td><td>n=19</td><td>Start at 25-50 mg/day and titrate to maintenance dose</td></tr>\n<tr><td>TPMT homozygote</td><td>n=0</td><td>Do not start azathioprine, use alternative treatment</td></tr>\n</tbody>\n</table>\n<table class=\"table\">\n<thead>\n<tr><th>Standard dosing arm (n=166)</th><th></th></tr>\n</thead>\n<tbody>\n<tr><td><strong>Genotype</strong></td><td><strong>Number</strong></td></tr>\n<tr><td>TPMT wild-type</td><td>n=150</td></tr>\n<tr><td>TPMT *1/*2, *1/*3A, or *1/*3C</td><td>n=15</td></tr>\n<tr><td>TPMT homozygote</td><td>n=1</td></tr>\n</tbody>\n</table>\n<h2 id=\"additional-findings\">Additional Findings</h2>\n<p>The single individual in the study who was homozygous for unspecified <em>TPMT</em> variant/s was in the standard dosing arm and experienced severe nonfatal neutropenia. In the genotyping arm, the average starting dose of azathioprine was lower in heterozygotes than wild-type (p=0.007).</p>\n<h2 id=\"additional-information\">Additional Information</h2>\n<ul>\n<li><strong>Ethnicity</strong>: England</li>\n<li><strong>Indication</strong>: Inflammatory disease</li>\n</ul>\n"},"sources":["PharmGKB"],"targets":[{"objCls":"Chemical","id":"PA448515","name":"azathioprine"},{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"}],"text":"||There was NO significant difference in likelihood of stopping azathioprine due to an adverse reaction when comparing patients who were dosed based on TPMT genotype and those who received a standard dose (p=0.59)||\r\n\r\n||Pharmacogenetic arm (n=167) - dosing advice for clinicians||\r\n|TPMT wild-type| n=148 |Maintenance dose of 1.5 - 3 mg/kg/day|\r\n|TPMT *1/*2, *1/*3A, or *1/*3C| n=19 |Start at 25-50 mg/day and titrate to maintenance dose|\r\n|TPMT homozygote| n=0 |Do not start azathioprine, use alternative treatment|\r\n\r\n||Standard dosing arm (n=166)||\r\n|TPMT wild-type| n=150 |\r\n|TPMT *1/*2, *1/*3A, or *1/*3C| n=15 |\r\n|TPMT homozygote| n=1 |\r\n\r\nThe single individual in the study who was *homozygous* for a TPMT variant (unspecified) and was in the standard dosing arm experienced severe nonfatal neutropenia.","type":"rx"}],"publication":{"id":14775937,"resourceId":"21692613","title":"A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21692613","type":"article"},"related":{"GENE":[{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"}],"DISEASE":[{"objCls":"Disease","id":"PA444620","name":"Inflammation"}],"HAPLOTYPE":[{"objCls":"Haplotype","id":"PA165819268","symbol":"TPMT*1","name":"*1","annotatable":true,"copyNumber":"1","gene":{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"},"hgvs":"NC_000006.11:g.[=]"},{"objCls":"Haplotype","id":"PA165819269","symbol":"TPMT*2","name":"*2","annotatable":true,"copyNumber":"1","gene":{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"},"hgvs":"NC_000006.11:g.[18143955C>G]"},{"objCls":"Haplotype","id":"PA165819270","symbol":"TPMT*3A","name":"*3A","annotatable":true,"copyNumber":"1","gene":{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"},"hgvs":"NC_000006.11:g.[18130918T>C;18139228C>T]"},{"objCls":"Haplotype","id":"PA165819272","symbol":"TPMT*3C","name":"*3C","annotatable":true,"copyNumber":"1","gene":{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"},"hgvs":"NC_000006.11:g.[18130918T>C]"}],"CHEMICAL":[{"objCls":"Chemical","id":"PA448515","name":"azathioprine"}]},"variantAnnotations":[{"cases":322,"characteristics":"Patients with inflammatory disease","chemicals":[{"current":true,"resource":"PharmGKB","text":"azathioprine","url":"/chemical/PA448515"}],"genes":[{"current":true,"resource":"PharmGKB","text":"TPMT","url":"/gene/PA356"}],"id":827811841,"literature":"21692613","literatureUrl":"/pmid/21692613","phenotypeCategories":["toxicity"],"pvalue":"0.74","race":"Mixed Population","significance":"no","variants":[{"current":true,"resource":"PharmGKB","text":"TPMT*1","url":"/haplotype/PA165819268"},{"current":true,"resource":"PharmGKB","text":"TPMT*2","url":"/haplotype/PA165819269"},{"current":true,"resource":"PharmGKB","text":"TPMT*3A","url":"/haplotype/PA165819270"},{"current":true,"resource":"PharmGKB","text":"TPMT*3C","url":"/haplotype/PA165819272"}]}]}